Research programme: therapeutic proteins - Multicell TechnologiesAlternative Names: Recombinant I(alpha)Ip - Multicell Technologies; Therapeutic protein for sepsis - Multicell Technologies
Latest Information Update: 08 Jun 2010
At a glance
- Originator MultiCell Technologies Inc
- Class Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 19 Oct 2005 Preclinical trials in Sepsis in USA (unspecified route)